Gut inflammation is commonly present in arthritis patients, linked to extensive disease and representing an important risk factor for the development of Crohn’s disease. Gut inflammation is evaluated through colonoscopy, a disturbing test for patients. Seeking for alternatives to reduce the number of colonoscopies, we supported the research of Prof. Dirk Elewaut at the VIB towards the development of a blood-based test that can predict gut inflammation in arthritis patients.
Biogazelle’s contribution included the profiling of a large panel of miRNA biomarker candidates in serum samples from arthritis patients. A biomarker signature was identified and validated in a second, independent patient cohort, paving the path towards the development of an RT-qPCR test to be implemented in the clinic.